Patents Examined by Michael G. Hartley
  • 2-[5-(imidazol-1-ylmethyl)pyridin-3-yl]benzimtdazole derivative compound, and medicament including same
    Patent number: 11266753
    Abstract: Provided are a compound represented by the following formula (1): wherein X1 represents a hydrogen atom or a halogen atom, X2 represents a fluorine atom or a nitrile group, and X3 represents a radioactive halogen atom, or a salt thereof, and a medicament including the same.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: March 8, 2022
    Assignees: NIHON MEDI-PHYSICS CO., LTD., NATIONAL HOSPITAL ORGANIZATION
    Inventors: Akihiro Izawa, Yuki Okumura, Yurie Fukui, Hiroaki Ichikawa, Yoshifumi Maya, Miho Ikenaga, Hiroyuki Okudaira, Yoshihiro Doi, Mitsuhide Naruse
  • Lipophilic macrocyclic ligands, complexes thereof, and uses of same
    Patent number: 11261166
    Abstract: The present invention relates to novel lipophilic macrocyclic ligands, the complexes thereof, in particular radioactive complexes, and the uses of same in medical imaging and/or in therapy, in particular in interventional radiology.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: March 1, 2022
    Assignee: GUERBET
    Inventors: Olivier Rousseaux, Olivier Fougere, Sarah Catoen
  • Compounds for use as iron(III) MRI contrast agents
    Patent number: 11261208
    Abstract: Provided are macrocyclic compounds and compounds with two or more macrocyclic groups, iron coordinated macrocyclic compounds, and iron coordinated compounds with two or more macrocyclic groups. The iron is high-spin iron(III). The iron coordinated compounds may exhibit a negative redox potential (e.g., relative to a normal hydrogen electrode at a biologically relevant pH, for example, a pH of 6.5-7.5). The compounds can be used as MRI contrast agents.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: March 1, 2022
    Assignee: The Research Foundation for The State University of New York
    Inventors: Janet R. Morrow, Eric M. Snyder, Didar Asik
  • Bioorthogonal compositions
    Patent number: 11253600
    Abstract: Cyclooctene conjugates of therapeutic or diagnostic agents have improved aqueous solubility and can release the agents upon contact with a tetrazine-containing biomaterial. The cyclooctene conjugates provide site-selective delivery of agents at the location of the tetrazine-containing biomaterial in a subject. The compositions and methods have applications in the treatment of various diseases or conditions including cancer, tumor growths, and bacterial infections.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: February 22, 2022
    Assignees: TAMBO, INC., THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Jose Manuel Mejia Oneto, Nathan Yee, Maksim Royzen, Sangeetha Srinivasan, Ethan Miller
  • Hemostatic microspheres
    Patent number: 11246938
    Abstract: Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: February 15, 2022
    Assignee: Baxter International Inc.
    Inventors: Richard I. Senderoff, Jeffrey D. Meyer, Emily N. Rollins, Steven D. Hughes, Richard M. Garcia, Paul D. Bishop, Gerald W. Lasser
  • Systems and methods for preparing tailored radioactive isotope solutions
    Patent number: 11250965
    Abstract: The present disclosure relates to systems and methods for producing tailored solutions or medicaments containing radioactive isotopes (e.g., alpha particle emitting radioactive isotopes). The solutions may be produced by appropriate aging and separation steps. Therapeutically effective amounts of Ac-225 and/or Bi-213 may thus be obtained.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: February 15, 2022
    Assignee: RADTRAN LLC
    Inventor: Saleem S. Drera
  • Imaging contrast agents and uses thereof
    Patent number: 11246949
    Abstract: Provided are macrocyclic compounds having a macrocyclic core which has at least one macrocyclic donor and at least one pendant group which has at least one donor group. The macrocyclic compounds can be complexed to Fe(II) and Ni(II). The macrocyclic compounds can be used in imaging methods. For example, the compounds can be used MRI paraCEST contrast agents.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: February 15, 2022
    Assignee: The Research Foundation for The State University of New York
    Inventors: Janet R. Morrow, Pavel Tsitovich, Sarina Dorazio, Abiola Olatunde
  • Near-infrared chemiluminescent probes for in-vivo imaging
    Patent number: 11241507
    Abstract: The present invention provides turn-ON dioxetane-based chemiluminescence probes based on the Schapp's adamantylidene-dioxetane probe, which emit light in the near-infrared (NIR) region and are therefore useful for in vivo imaging, as well as compositions and uses thereof.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: February 8, 2022
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Doron Shabat, Ori Green
  • Synthesizing pet tracers using [F-18]sulfonyl fluoride as a source of [F-18]fluoride
    Patent number: 11242314
    Abstract: The present disclosure relates to the methods for the preparation of reactive [F-18]fluoride in a form of [F-18]sulfonyl fluoride suitable for efficient radiolabeling without an azeotropic evaporation step by the use of anion exchange resin and sulfonyl chloride, and its applications in the manufacturing of PET radiopharmaceuticals.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: February 8, 2022
    Assignee: Washington University
    Inventors: Dong Zhou, Wenhua Chu
  • Hydrophilic fluorinated molecules for liposomal 19F MRI probes with unique MR signatures
    Patent number: 11241510
    Abstract: Readily available hydrophilic and small organofluorine moieties were condensed via “click chemistry” to generate nonionic hydrophilic fluorinated molecules with unique 19F MR signatures. These were used to fabricate stable liposome formulations for imaging various tissue types. This approach was tailored to exploit the broad spectrum of organic 19F molecular species and to generate probes with distinct 19F MRI signatures for simultaneous assessment of multiple molecular targets within the same target volume.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: February 8, 2022
    Assignee: TEXAS CHILDREN'S HOSPITAL
    Inventors: Ananth Annapragada, Eric A. Tanifum
  • Contrast agents for magnetic resonance imaging
    Patent number: 11235074
    Abstract: Ascorbate or a pharmaceutically acceptable salt thereof is described for use in carrying out a method, or for the preparation of a medicament for carrying out a method, of enhancing a magnetic resonance imaging (MRI) image of a body or body region such as an organ or organ region in a subject. The method is carried out by parenterally administering ascorbate or a pharmaceutically acceptable salt thereof to the subject in an MRI image-enhancing amount; and then generating, by MRI of the subject, an image of the body or body region. The ascorbate or pharmaceutically acceptable salt thereof enhances the MRI image.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: February 1, 2022
    Assignee: Duke University
    Inventor: Christopher David Lascola
  • Peptide hydrogels generating chemical exchange saturation transfer MRI contrast and uses thereof
    Patent number: 11235075
    Abstract: The present invention provides novel hydrogels through peptides, which are designed to self-assemble and produce magnetic resonance (MR) contrast through chemical exchange saturation transfer (CEST). The location and integrity of these gels could consequently be tracked using MR imaging. The self-assembly of the peptides into hydrogels can be brought about by a change in pH, ionic strength, temperature, and concentration of ions.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: February 1, 2022
    Assignees: THE JOHNS HOPKINS UNIVERSITY, KENNEDY KRIEGER INSTITUTE, INC., NATIONAL INSTITUTES OF HEALTH
    Inventors: Michael T. McMahon, Kannie Wai-Yan Chan, Michael Christopher Giano, Nikita Oskolkov, Joel Patrick Schneider, Xiaolei Song
  • Chelated PSMA inhibitors
    Patent number: 11225496
    Abstract: Provided herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. Also provided are compositions including a compound of Formula (I) together with a pharmaceutically acceptable carrier, and methods for imaging prostate cancer cells.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: January 18, 2022
    Assignee: Cancer Targeted Technology LLC
    Inventors: Clifford Berkman, Cindy Choy
  • Process for the production of an abuse-proofed dosage form
    Patent number: 11224576
    Abstract: The present invention relates to a process for the production of abuse-proofed, thermoformed dosage forms containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: January 18, 2022
    Assignee: GRÜNENTHAL GMBH
    Inventors: Elisabeth Arkenau-Marić, Johannes Bartholomäus
  • Gadolinium contrast agents, scavenging methods, and scavenging system
    Patent number: 11224666
    Abstract: A functional gadolinium contrast agent comprising a gadolinium cation and a ligand secured to the gadolinium cation is disclosed, the ligand comprising a reactive group capable of bonding to a capture substrate. A method of removing gadolinium contrast agents from a patient is disclosed, the method comprising providing a gadolinium contrast agent containing a reactive group; providing a capture substrate for insertion into a patient's bloodstream; administering the gadolinium contrast agent to the patient; conducting a magnetic resonance imaging procedure; and sequestering the gadolinium contrast agent on the capture substrate. A system for removing gadolinium contrast agents is also disclosed.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: January 18, 2022
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Joseph Thomas Delaney, Jr., Douglas Dean Pagoria, Douglas Pennington, Paul Sorajja
  • Compositions and methods to detect GluA1 in brain and to identify the presence of GluA1-mediated PTSD
    Patent number: 11224668
    Abstract: The present invention provides compositions and methods for detecting GluA1, as a subunit protein and/or as a GluA1-containing, GluA2-lacking AMPAR complex. The invention further provides composition and methods for detecting and/or diagnosing PTSD. The invention further relates to compositions that can be detected using radiological imaging techniques, and processes for performing such imaging techniques using the compositions, to identify elevated GluA1 expression or activity in a subject, which is a biological marker of PTSD.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: January 18, 2022
    Assignee: NEUROVATION LABS, INC.
    Inventor: Jennifer Perusini
  • Method for producing a fraction of Xenon radioisotopes, in particular Xe-133, fraction of Xenon radioisotopes, in particular Xe-133
    Patent number: 11227699
    Abstract: A method for producing a fraction of xenon radioisotopes, comprising the steps of dissolving enriched uranium targets forming a slurry and a gaseous phase containing xenon radioisotopes, isolating the xenon radioisotopes using zeolite doped with silver, preferably chosen from the group consisting of aluminosilicates doped with silver, titanosilicates doped with silver and mixtures thereof, and recovering the fraction of xenon radioisotopes, in particular Xe-133.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: January 18, 2022
    Assignee: Institut National Des Radioeléménts
    Inventors: Philippo Faga, Dominique Moyaux, Benoit Deconninck
  • Metal oxide nanoparticle-based T1-T2 dual-mode magnetic resonance imaging contrast agent
    Patent number: 11219698
    Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly a metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent that can be used not only as a T1 MRI contrast agent but also as a T2 MRI contrast agent, and a method for producing the same. The metal oxide nanoparticle-based T1-T2 dual-mode MRI contrast agent can provide more accurate and detailed information associated with disease than single MRI contrast agent by the beneficial contrast effects in both T1 imaging with high tissue resolution and T2 imaging with high feasibility on detection of a lesion.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: January 11, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Kwang Yeol Lee, Min Sik Kim, Taek Hoon Kim, Ngoc Phan Vu
  • Boron enriched linker (“BEL”) compositions for boron neutron capture therapy and methods thereof
    Patent number: 11219689
    Abstract: Boron Enriched Linker (“BEL”) compositions and methods of making BELs are disclosed herein. Consequently, the BELs can be conjugated to antibodies or antibody fragments to create Antibody Boron Conjugates (“ABCs”) to provide a method of treating cancer, immunological disorders and other disease by utilizing a Neutron Capture Therapy modality.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: January 11, 2022
    Assignee: TAE Life Sciences, LLC
    Inventors: Michael Y. Torgov, Tioga J. Martin
  • Radiocontrast agents, scavenging methods, and scavenging system
    Patent number: 11213596
    Abstract: An imaging contrast composition comprising an iodinated contrast agent and a ligand secured to the iodinated contrast agent is disclosed, the ligand comprising a reactive group capable of bonding to a capture substrate. A method of removing iodinated radiocontrast agents from a patient is disclosed, the method comprising providing an iodinated radiocontrast agent containing a reactive group; providing a capture substrate for insertion into a patient's bloodstream; administering the iodinated radiocontrast agent to the patient; conducting procedure CT scan or procedure using fluoroscopy; and sequestering the iodinated radiocontrast agent on the capture substrate.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: January 4, 2022
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Joseph Thomas Delaney, Jr., Douglas Dean Pagoria, Richard Lee Tadsen, Andrew J. Ro, Joel T. Eggert, Douglas Pennington, Paul Sorajja, Sarah Melissa Gruba, Tatyana Dyndikova